Erratum to: Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: Possible role of epigenetic regulation (Molecular Biology Reports DOI: 10.1007/s11033-014-3392-2);Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: Possible role of epigenetic regulation

Molecular Biology Reports

Volumn 41, Issue 8, 2014, Pages 4853-4863

  Amber, Cicek Figen ^a   Zeynep, Tokcaer Keskin ^a   Evren, Ozcinar ^a   Yusuf, Bozkus ^b   Can, Akcali Kamil ^a   Belma, Turan ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Epigenetic; Gliptins; Hyperglycemia; Metabolic syndrome; Vascular function

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HISTONE METHYLTRANSFERASE; PROTEIN H3K27ME3; PROTEIN KINASE B; SITAGLIPTIN; SUCROSE; UNCLASSIFIED DRUG; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HISTONE; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DIETARY INTAKE; DRUG MECHANISM; ENZYME PHOSPHORYLATION; EPIGENETICS; GLYCEMIC CONTROL; HEART MUSCLE RELAXATION; HYPERGLYCEMIA; MALE; METABOLIC SYNDROME X; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROCESSING; RAT; SIGNAL TRANSDUCTION; THORACIC AORTA; VASCULAR ENDOTHELIUM; VASCULAR RING; ANALYSIS OF VARIANCE; ANIMAL; AORTA; CHEMICALLY INDUCED; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC EPIGENESIS; PATHOLOGY; PHYSIOLOGY; VASODILATATION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; AORTA; BLOTTING, WESTERN; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EPIGENESIS, GENETIC; FLUORESCENT ANTIBODY TECHNIQUE; HISTONES; METABOLIC SYNDROME X; PYRAZINES; RATS; SUCROSE; TRIAZOLES; VASODILATION;

EID: 84904982045     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3674-8     Document Type: Erratum

References (45)

1. Capes SE, Hunt D, Malmberg K, Gerstein HC (2000) Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355(9206):773-778. doi:10.1016/S0140-6736(99)08415-9 (Pubitemid 30128815)
2. Lee CD, Folsom AR, Pankow JS, Brancati FL, Atherosclerosis Risk in Communities Study I (2004) Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 109(7):855-860. doi:10.1161/01.CIR.0000116389.61864.DE (Pubitemid 38252737)
3. Huang PL (2005) Unraveling the links between diabetes, obesity, and cardiovascular disease. Circ Res 96(11):1129-1131. doi:10.1161/01.RES. 0000170705.56583.45
4. Fox CS, Coady S, Sorlie PD, D'Agostino RB Sr, Pencina MJ, Vasan RS, Meigs JB, Levy D, Savage PJ (2007) Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115(12):1544-1550. doi:10.1161/CIRCULATIONAHA.106.658948 (Pubitemid 46648639)
5. Dinh W, Lankisch M, Nickl W, Gies M, Scheyer D, Kramer F, Scheffold T, Krahns T, Sause A, Futh R (2011) Metabolic syndrome with or without diabetes contributes to left ventricular diastolic dysfunction. Acta Cardiol 66(2):167-174
6. Cardillo C (2013) Drug treatments to restore vascular function and diabesity. Ann Pharm Fr 71(1):27-33. doi:10.1016/j.pharma.2012.09.001
7. D'Souza A, Hussain M, Howarth FC, Woods NM, Bidasee K, Singh J (2009) Pathogenesis and pathophysiology of accelerated atherosclerosis in the diabetic heart. Mol Cell Biochem 331(1-2):89-116. doi:10.1007/s11010-009-0148-8
8. Goodwill AG, Frisbee JC (2012) Oxidant stress and skeletal muscle microvasculopathy in the metabolic syndrome. Vasc Pharmacol 57(5-6):150-159. doi:10.1016/j.vph.2012.07.002
9. Nade VS, Kawale LA, Todmal UB, Tajanpure AB (2012) Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats. Indian J Pharmacol 44(6):688-693. doi:10.4103/0253-7613. 103248
10. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ (2002) Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 76(5):911-922 (Pubitemid 35244659)
11. Katakam PV, Ujhelyi MR, Hoenig ME, Miller AW (1998) Endothelial dysfunction precedes hypertension in diet-induced insulin resistance. Am J Physiol 275(3 Pt 2):R788-R792
12. Mikhail N (2008) Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vasc Health Risk Manag 4(6):1221-1227
13. Chinda K, Chattipakorn S, Chattipakorn N (2012) Cardioprotective effects of incretin during ischaemia-reperfusion. Diabetes Vasc Dis Res: Off J Int Soc Diabetes Vasc Dis 9(4):256-269. doi:10.1177/1479164112440816
14. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M (2012) Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 11(5):384-400. doi:10.1038/nrd3674
15. Chaudhary N, Nakka KK, Maulik N, Chattopadhyay S (2012) Epigenetic manifestation of metabolic syndrome and dietary management. Antioxid Redox Signal 17(2):254-281. doi:10.1089/ars.2011.4387
16. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548):1696-1705. doi:10.1016/S0140-6736(06)69705-5 (Pubitemid 46048557)
17. McIntosh CH (2008) Dipeptidyl peptidase IV inhibitors and diabetes therapy. Front Biosci J Virtual Libr 13:1753-1773 (Pubitemid 351599730)
18. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H (2008) Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol 588(2-3):325-332. doi:10.1016/j.ejphar. 2008.04.018
19. Shah Z, Pineda C, Kampfrath T, Maiseyeu A, Ying Z, Racoma I, Deiuliis J, Xu X, Sun Q, Moffatt-Bruce S, Villamena F, Rajagopalan S (2011) Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vasc Pharmacol 55(1-3):2-9. doi:10.1016/j.vph.2011.03.001
20. Neumiller JJ, Wood L, Campbell RK (2010) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 30(5):463-484. doi:10.1592/phco.30.5.463
21. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H (2009) Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and betacell function in db/db mice. Br J Pharmacol 157(3):415-426. doi:10.1111/j.1476-5381.2009.00145.x
22. Zeydanli EN, Bilginoglu A, Tanriverdi E, Gurdal H, Turan B (2010) Selenium restores defective beta-adrenergic receptor response of thoracic aorta in diabetic rats. Mol Cell Biochem 338(1-2):191-201. doi:10.1007/s11010-009- 0353-5
23. ZeydanliEN,KandilciHB,TuranB(2011)Doxycycline ameliorates vascular endothelial and contractile dysfunction in the thoracic aorta of diabetic rats. Cardiovasc Toxicol 11(2):134-147. doi:10.1007/s12012-011-9107-1
24. Bailey T (2013) Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med 126(9 Suppl 1):S10-S20. doi:10.1016/j.amjmed.2013.06.009
25. Monami M, Lamanna C, Desideri CM, Mannucci E (2012) DPP- 4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 29(1):14-25. doi:10.1007/s12325-011-0088-z
26. Tziomalos K, Kirkineska L, Baltatzi M, Efthymiou E, Psianou K, Papastergiou N, Magkou D, Zervopoulos G, Kagelidis G, Karlafti E, Savopoulos C, Hatzitolios AI (2013) Prevalence of resistant hypertension in 1810 patients followed up in a specialized outpatient clinic and its association with the metabolic syndrome. Blood Press 22(5):307-311. doi:10.3109/08037051.2013.765632
27. Limberg JK, Harrell JW, Johansson RE, Eldridge MW, Proctor LT, Sebranek JJ, Schrage WG (2013) Microvascular function in younger adults with obesity and metabolic syndrome: role of oxidative stress. Am J Physiol Heart Circ Physiol 305(8):H1230-H1237. doi:10.1152/ajpheart.00291.2013
28. Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, Sowers J (2013) Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens 15(1):14-33. doi:10.1111/jch.12049
29. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA (2008) Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 48(5):592-598. doi:10.1177/0091270008316885 (Pubitemid 351503521)
30. Patel A, Group AC, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370(9590):829-840. doi:10.1016/S0140-6736(07)61303-8 (Pubitemid 47362321)
31. Jackson EK, Dubinion JH, Mi Z (2008) Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure. Clin Exp Pharmacol Physiol 35(1):29-34. doi:10.1111/j.1440-1681.2007.04737.x (Pubitemid 350197677)
32. Balakumar P, Dhanaraj SA (2013) Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. Cell Signal 25(9):1799-1803. doi:10.1016/j.cellsig.2013. 05.009
33. Creager MA, Luscher TF, Cosentino F, Beckman JA (2003) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108(12):1527-1532. doi:10.1161/01.CIR.0000091257.27563.32 (Pubitemid 37176462)
34. MasonRP, JacobRF, Kubant R,WalterMF,Bellamine A, Jacoby A, Mizuno Y, Malinski T (2011) Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb 18(9):774-783
35. Hamuro M, Polan J, Natarajan M, Mohan S (2002) High glucose induced nuclear factor kappa B mediated inhibition of endothelial cell migration. Atherosclerosis 162(2):277-287 (Pubitemid 34460700)
36. Ding L, Zhang J (2012) Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin 33(1):75-81. doi:10.1038/aps.2011.149
37. Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y (2012) Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 60(3):833-841. doi:10.1161/HYPERTENSIONAHA.112.195115
38. Pacheco BP, Crajoinas RO, Couto GK, Davel AP, Lessa LM, Rossoni LV, Girardi AC (2011) Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 29(3):520-528. doi:10.1097/HJH.0b013e328341939d
39. Kubota Y, Miyamoto M, Takagi G, Ikeda T, Kirinoki-Ichikawa S, Tanaka K, Mizuno K (2012) The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci 27(11):1364-1370. doi:10.3346/jkms.2012.27.11.1364
40. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H (2013) Dipeptidyl peptidase- 4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 77(5):1337-1344
41. Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A, Paolisso G (2013) Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 227(2):349-354. doi:10.1016/j.atherosclerosis.2012.12.018
42. Justin N, De Marco V, Aasland R, Gamblin SJ (2010) Reading, writing and editing methylated lysines on histone tails: new insights from recent structural studies. Curr Opin Struct Biol 20(6):730-738. doi:10.1016/j.sbi.2010.09.012
43. Mansour AA, Gafni O, Weinberger L, Zviran A, Ayyash M, Rais Y, Krupalnik V, Zerbib M, Amann-Zalcenstein D, Maza I, Geula S, Viukov S, Holtzman L, Pribluda A, Canaani E, Horn-Saban S, Amit I, Novershtern N, Hanna JH (2012) The H3K27 demethylase Utx regulates somatic and germ cell epigenetic reprogramming. Nature 488(7411):409-413. doi:10.1038/nature11272
44. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24):2457-2471. doi:10.1056/NEJMoa072761 (Pubitemid 46919772)
45. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 304(4):411-418. doi:10.1001/jama.2010.920